Clinical Advances in BTK Inhibitors for Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Where disease-, treatment-, and patient-centric education unite.

CME Education Series

To access individual CME activity information and to participate, please click the participation button above.

Patient Education: Click here to access education for your CLL patients on how to work with their healthcare team.

Target Audience

This activity is intended for hematology/oncology specialists and other members of the oncology multidisciplinary team.

Description

The evolving treatment landscape of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) is evolving with novel therapies that may overcome the challenges of resistance and disease progression. With that in mind, this Clinical Advances in BTK Inhibitors for Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Where Disease-, Treatment-, and Patient-Centric Education Unite was created to provide a broad range of educational activities on ongoing therapeutic developments and patient-centered care throughout the care continuum in a variety of program formats to appeal to your individual learning preferences.

Activity Topics

Optimizing Treatment Pathways in CLL and MCL: Evaluating and Applying Recent Data on BTK Inhibitors.
There Are Multiple Ways to Treat R/R CLL or R/R MCL: What Would the Experts Do?
Navigating Patient-Centered Care of CLL and MCL: Empowering Collaboration and Communication
Chronic Lymphocytic Leukemia Case Simulation: Put Your Skills to the Test

Providers

This activity is developed through a collaboration between The Leukemia & Lymphoma Society and Medscape Oncology.

Supporters

This activity is supported by an independent educational grant from Lilly.

For questions, concerns, or assistance for people with disabilities or grievances, please contact LLS at: profeducation@LLS.org.